Starpharma Holdings Ltd has released a press release.
DEP irinotecan combination outperforms in colon cancel model
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- First VivaGel BV launch globally in Australia by Aspen
- Starpharma receives $4.0M R&D tax incentive refund
- Interim Report and Half-Yearly Financial Results
- Response to ASX Aware Letter
- VivaGel condom receives final regulatory approval in Japan
Later from Starpharma
- Starpharma signs second oncology agreement with AstraZeneca
- VivaGel BV launched in Europe
- Starpharma commences phase 1/2 DEP irinotecan trial
- First Asian Regulatory Approvals Received for VivaGel BV
- Promising efficacy signals observed in ongoing DEP trials
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma